Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.

PloS one - 1 Jan 2020

Gostelie Romee, Stegeman Inge, Berkers Gitte, Bittermann Joost, Ligtenberg-van der Drift Ivonne, Kipshagen Peter-Jan van, de Winter-de Groot Karin, Speleman Lucienne

Abstract excerpt

IMPORTANCE: Sinonasal symptoms in patients suffering from cystic fibrosis can negatively influence the quality of life and sinuses can be a niche for pathogens causing infection and inflammation leading to a decrease of lung function. Ivacaftor, a potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator protein, has shown improvement in pulmonary function in cystic fibrosis patients with different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Chloride Channel Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Nitric Oxide

Share to Quinolones

Share to Tertiary Care Centers

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 32687499
DOI: 10.1371/journal.pone.0235638
PMCID: PMC7371187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.PMID 32687499Read ↗

Systematic review of nasal endoscopy scores in cystic fibrosis patients treated with CFTR modulatorsSemantic proximity Read ↗

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.Semantic proximity Read ↗

Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.Semantic proximity Read ↗

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Semantic proximity Read ↗

Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.Semantic proximity Read ↗

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read ↗

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215NSemantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.Semantic proximity Read ↗

CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.Semantic proximity Read ↗

Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.Semantic proximity Read ↗

The Evaluation of the Genotype and Phenotype Relationship in Patients With Nasal Polyps in Cystic Fibrosis Registry of Turkey.Semantic proximity Read ↗

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.